Drug discovery

Cancer cells
#Biomarkers #Drug discovery #Evotec #Immunoassays #Webinar

Webinar explores applying ultrasensitive immunoassays for clinical biomarkers

When biomarkers are present at very low concentrations, conventional immunoassays may not provide the sensitivity needed to generate reliable, meaningful data. This can limit the ability to assess target engagement, monitor pharmacodynamic responses and track biomarker changes during treatment. Ultrasensitive immunoassays offer new opportunities to address these challenges. In this… Read More

#News

Digital biomarkers
#Biomarkers #Drug discovery #Evotec #Webinar

Webinar connects PK/PD biomarkers with decision-making

Clinical trials continue to experience high attrition rates, with lack of efficacy being one of the leading causes of failure. However, in many cases, these failures do not reflect a lack of drug efficacy, but rather limitations in translational biomarker strategies and selection of disease-relevant pharmacodynamic (PD) biomarkers, suboptimal dose… Read More

#News

#ALLOX #Artificial intelligence (AI) #Drug discovery #Financing #Seed funding

ALLOX closes $10.5m financing to scale allosteric discovery platform

ALLOX has announced the successful closing of its $10.5 million (€9.4m) seed financing round and the appointment of Morten Graugaard as Independent Chair of its Board of Directors.   The round was led by Asabys, through its Sabadell Asabys II fund, with participation from CDTI with its SICC… Read More

#Business & Investment #News #Start-up Zone

Vaccine research
#Contract Research Organisations (CROs) #Drug discovery #Preclinical development #Whitepaper

Whitepaper: How important is onshoring preclinical research?

This Whitepaper by Crown Bioscience outlines the onshoring strategies for pharmaceutical companies and how this affects decisions to work with contract research organisations (CRO) at home or abroad. Readers will learn: The regulatory developments driving onshoring strategies Industry considerations for choosing a CRO When onshoring needs to be considered Download… Read More

#Editor's Choice #News

Berlin cityscape
#BioInnovation Institute #Biotech #Cardiometabolic diseases #Drug discovery #Europe

German hubs selected for BII cardiometabolic research initiative

BioInnovation Institute (BII) has selected Munich and Berlin as the locations for its German activities under the CardioMetabolic Bridge (CMB) initiative.   The expansion marks another important milestone in BII’s ambition to build a connected European innovation ecosystem dedicated to accelerating the development of new treatments for cardiometabolic… Read More

#News

Biomarkers concept
#Biomarkers #Drug discovery #Evotec #Webinar

Webinar: PK/PD and QSP modeling in translational biomarker development

Clinical trials continue to experience high attrition rates, with lack of efficacy being one of the leading causes of failure. However, in many cases, these failures do not reflect a lack of drug efficacy, but rather limitations in translational biomarker strategies and selection of disease-relevant pharmacodynamic (PD) biomarkers, suboptimal dose… Read More

#News

#AI / data analytics / healthtech / informatics #DDII #DDIIDigitalForum #Drug discovery #Investment #Technology

This week in Drug Discovery (26-30 October)

News round-up for 26-30 October 2026 by Megan Thomas, Multimedia Editor at DDW.  This week’s news roundup covers the upcoming Drug Discovery Innovators & Investors Conference in London, as well as four stories that showcase the far reaching impact of artificial intelligence (AI) in drug discovery. The… Read More

#News

#Biomarkers #Drug discovery #Evotec #Immunoassays #Webinar

Measuring what matters: Applying ultrasensitive immunoassays for clinical biomarkers

When biomarkers are present at very low concentrations, conventional immunoassays may not provide the sensitivity needed to generate reliable, meaningful data. This can limit the ability to assess target engagement, monitor pharmacodynamic responses and track biomarker changes during treatment. Ultrasensitive immunoassays offer new opportunities to address these challenges. In this… Read More

Webinar date:
Supported by Evotec
#Featured Webinars #Webinars

#Biomarkers #Drug discovery #Evotec #Immunoassays #Webinar

New webinar: Applying ultrasensitive immunoassays for clinical biomarkers

When biomarkers are present at very low concentrations, conventional immunoassays may not provide the sensitivity needed to generate reliable, meaningful data. This can limit the ability to assess target engagement, monitor pharmacodynamic responses and track biomarker changes during treatment. Ultrasensitive immunoassays offer new opportunities to address these challenges. In this… Read More

#News

#AI / data analytics / healthtech / informatics #Drug discovery #Insilico Medicine #Servier

Partnership advances AI-driven R&D collaboration 

Insilico Medicine has achieved the early drug discovery milestone in its multi-year AI-driven drug discovery collaboration with pharmaceutical group Servier.  Under the collaboration, the two companies initiated two distinct R&D programmes for oncology on challenging targets leveraging Insilico’s proprietary end-to-end AI platform, Pharma.AI. Target nominations have been… Read More

#News

#Crown Bioscience #Drug discovery #PDX models #Webinar

Webinar: Exploring warm PDX benefits and onsite expertise

Patient-derived xenograft (PDX) models are a valuable tool in oncology research, helping researchers evaluate therapeutic efficacy in preclinical settings using models that retain key characteristics of human tumours. In this webinar, Crown Bioscience will highlight the capabilities of its PDX model portfolio, with a particular focus on the benefits of… Read More

#News

#Crown Bioscience #Drug discovery #PDX models #Webinar

Beyond the model: Exploring warm PDX benefits and onsite expertise

Patient-derived xenograft (PDX) models are a valuable tool in oncology research, helping researchers evaluate therapeutic efficacy in preclinical settings using models that retain key characteristics of human tumours. In this webinar, Crown Bioscience will highlight the capabilities of its PDX model portfolio, with a particular focus on the benefits of… Read More

Webinar date:
Supported by Crown Bioscience
#Featured Webinars #Webinars

London skyline
#DDII #DDIIeventseries #DDIIUK2026 #Drug development #Drug discovery #Events

Next week: DDW’s Drug Discovery Innovators and Investors (DDII) conference

DDW’s Drug Discovery Innovators and Investors (DDII) conference returns to London on 4 November, bringing together leaders from pharma and biotech, technology suppliers, academia, start-ups, spin-outs and the investment community. Date: Wednesday, 4 November 2026 Time: 09:00–17:00 Venue: etc.venues Monument, 8 Eastcheap, London, EC3M 1AE The one-day conference will explore… Read More

#News